Angela Walsh - Dogwood Therapeutics, Secretary Officer
| DWTX Stock | 6.83 0.92 15.57% |
Executive
Angela Walsh is Secretary Officer of Dogwood Therapeutics,
| Age | 59 |
| Phone | 866 620 8655 |
| Web | https://www.dwtx.com |
Angela Walsh Latest Insider Activity
Tracking and analyzing the buying and selling activities of Angela Walsh against Dogwood Therapeutics, stock is an integral part of due diligence when investing in Dogwood Therapeutics,. Angela Walsh insider activity provides valuable insight into whether Dogwood Therapeutics, is net buyers or sellers over its current business cycle. Note, Dogwood Therapeutics, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Dogwood Therapeutics,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Angela Walsh over six months ago Acquisition by Angela Walsh of 2000 shares of Virios Therapeutics at 4.575 subject to Rule 16b-3 |
Dogwood Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.9664) % which means that it has lost $0.9664 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0048) %, meaning that it created substantial loss on money invested by shareholders. Dogwood Therapeutics,'s management efficiency ratios could be used to measure how well Dogwood Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Walter Ripple | Avient Corp | N/A | |
| Bob McKinzie | National Vision Holdings | N/A | |
| Kevin Lilly | Jeld Wen Holding | 65 | |
| Joe VanDette | National Vision Holdings | 47 | |
| Daniel Valenti | Jeld Wen Holding | 47 | |
| Matthew Meier | Jeld Wen Holding | 52 | |
| Megan Molony | National Vision Holdings | 58 | |
| David CFA | National Vision Holdings | N/A | |
| Wendy Livingston | Jeld Wen Holding | 51 | |
| Caryn Klebba | Jeld Wen Holding | N/A | |
| Tamara Gonzalez | National Vision Holdings | N/A | |
| James Armstrong | Jeld Wen Holding | N/A | |
| Ryan Swedburg | Eldorado Gold Corp | N/A | |
| Melissa Rasmussen | National Vision Holdings | 47 | |
| Claire Chamberlain | Eldorado Gold Corp | N/A | |
| Jacqueline Grove | National Vision Holdings | N/A | |
| Kurt Schuering | Avient Corp | 60 | |
| Richard CPA | Olympic Steel | 56 | |
| Michelle SPHR | Olympic Steel | N/A | |
| Nora Lozano | Eldorado Gold Corp | N/A | |
| John Weaver | IPG Photonics | N/A | |
Management Performance
| Return On Equity | -2.0 | ||||
| Return On Asset | -0.97 |
Dogwood Therapeutics, Leadership Team
Elected by the shareholders, the Dogwood Therapeutics,'s board of directors comprises two types of representatives: Dogwood Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dogwood. The board's role is to monitor Dogwood Therapeutics,'s management team and ensure that shareholders' interests are well served. Dogwood Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dogwood Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Duncan, Chairman CEO | ||
| Carol Duffy, Chief Advisor | ||
| William MD, Founder Board | ||
| Ralph MPH, Senior Operations | ||
| Angela Walsh, Secretary Officer |
Dogwood Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dogwood Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.0 | ||||
| Return On Asset | -0.97 | ||||
| Current Valuation | 6.13 M | ||||
| Shares Outstanding | 1.33 M | ||||
| Shares Owned By Insiders | 21.48 % | ||||
| Shares Owned By Institutions | 2.44 % | ||||
| Number Of Shares Shorted | 38.19 K | ||||
| Price To Book | 8.60 X | ||||
| Net Income | (5.3 M) | ||||
| Total Debt | 358.55 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Dogwood Stock Analysis
When running Dogwood Therapeutics,'s price analysis, check to measure Dogwood Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dogwood Therapeutics, is operating at the current time. Most of Dogwood Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Dogwood Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dogwood Therapeutics,'s price. Additionally, you may evaluate how the addition of Dogwood Therapeutics, to your portfolios can decrease your overall portfolio volatility.